http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 18 Sep 2024 07:36:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Medivir+to+present+at+the+Pareto+Securities+Healthcare+Conference/23735218.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(Nasdaq Stockholm: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, today announces that the company will present at the <span>Pareto Securities Healthcare Conference</span> tomorrow, <chron>September 19</chron>.</p> <p>CEO <person>Jens Lindberg</person> will provide an update on the mature and detailed data from the phase 1b/2a study with fostrox-+ Lenvima^® in advanced hepatocellular carcinoma (HCC) recently presented at the ESMO conference.</p> <p><b>The presentation will be available on Medivir's website after the meeting.</b></p> <p>For more information about the event, please visit <a target="_blank" http://www.streetinsider.com/Press+Releases/Medivir+to+present+at+the+Pareto+Securities+Healthcare+Conference/23735218.html Wed, 18 Sep 2024 07:36:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Medivir+to+present+at+the+Pareto+Securities+Healthcare+Conference/23735218.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(Nasdaq Stockholm: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, today announces that the company will present at the <span>Pareto Securities Healthcare Conference</span> tomorrow, <chron>September 19</chron>.</p> <p>CEO <person>Jens Lindberg</person> will provide an update on the mature and detailed data from the phase 1b/2a study with fostrox-+ Lenvima^® in advanced hepatocellular carcinoma (HCC) recently presented at the ESMO conference.</p> <p><b>The presentation will be available on Medivir's website after the meeting.</b></p> <p>For more information about the event, please visit <a target="_blank" http://www.streetinsider.com/PRNewswire/Medivir+to+present+at+the+Pareto+Securities+Healthcare+Conference/23735218.html Wed, 18 Sep 2024 07:36:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Medivir+to+present+at+the+Pareto+Securities+Healthcare+Conference/23735218.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(Nasdaq Stockholm: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, today announces that the company will present at the <span>Pareto Securities Healthcare Conference</span> tomorrow, <chron>September 19</chron>.</p> <p>CEO <person>Jens Lindberg</person> will provide an update on the mature and detailed data from the phase 1b/2a study with fostrox-+ Lenvima^® in advanced hepatocellular carcinoma (HCC) recently presented at the ESMO conference.</p> <p><b>The presentation will be available on Medivir's website after the meeting.</b></p> <p>For more information about the event, please visit <a target="_blank" http://www.streetinsider.com/Press+Releases/Medivir+to+present+at+the+Pareto+Securities+Healthcare+Conference/23735218.html Wed, 18 Sep 2024 07:36:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Medivir+to+present+at+the+Pareto+Securities+Healthcare+Conference/23735218.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Sept. 18, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(Nasdaq Stockholm: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, today announces that the company will present at the <span>Pareto Securities Healthcare Conference</span> tomorrow, <chron>September 19</chron>.</p> <p>CEO <person>Jens Lindberg</person> will provide an update on the mature and detailed data from the phase 1b/2a study with fostrox-+ Lenvima^® in advanced hepatocellular carcinoma (HCC) recently presented at the ESMO conference.</p> <p><b>The presentation will be available on Medivir's website after the meeting.</b></p> <p>For more information about the event, please visit <a target="_blank" http://www.streetinsider.com/PRNewswire/Medivir+to+present+at+the+Pareto+Securities+Healthcare+Conference/23735218.html Wed, 18 Sep 2024 07:36:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Medivir%27s+fostrox+%2B+Lenvima+confirm+promise+of+improved+outcomes+in+advanced+liver+cancer%2C+detailed+and+mature+data+presented+at+ESMO/23723647.html <div class="xn-content"> <ul type="disc"><li><i>Mature results from Medivir's phase 1b / 2a open label trial of fostrox + Lenvima® confirm improved outcomes in second-line advanced liver cancer with a median time to progression (TTP) of 10.9 months¹ (4.1 – 18.1).</i></li><li><i>The results showed an objective response (ORR) of 24%, and a median duration of response of 7.0 months.</i></li><li><i>Detailed safety update reinforces the ability to combine fostrox and Lenvima long-term, only 1 patient discontinuing fostrox due to adverse events.</i></li><li><i>Medivir's fostrox (fostroxacitabine bralpamide) is the only orally-administered, liver-targeted inhibitor of DNA replication. Its unique mechanism for the treatment of liver cancer delivers the cell-killing compound selectively http://www.streetinsider.com/Press+Releases/Medivir%27s+fostrox+%2B+Lenvima+confirm+promise+of+improved+outcomes+in+advanced+liver+cancer%2C+detailed+and+mature+data+presented+at+ESMO/23723647.html Mon, 16 Sep 2024 03:21:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Medivir%27s+fostrox+%2B+Lenvima+confirm+promise+of+improved+outcomes+in+advanced+liver+cancer%2C+detailed+and+mature+data+presented+at+ESMO/23723647.html <div class="xn-content"> <ul type="disc"><li><i>Mature results from Medivir's phase 1b / 2a open label trial of fostrox + Lenvima® confirm improved outcomes in second-line advanced liver cancer with a median time to progression (TTP) of 10.9 months¹ (4.1 – 18.1).</i></li><li><i>The results showed an objective response (ORR) of 24%, and a median duration of response of 7.0 months.</i></li><li><i>Detailed safety update reinforces the ability to combine fostrox and Lenvima long-term, only 1 patient discontinuing fostrox due to adverse events.</i></li><li><i>Medivir's fostrox (fostroxacitabine bralpamide) is the only orally-administered, liver-targeted inhibitor of DNA replication. Its unique mechanism for the treatment of liver cancer delivers the cell-killing compound selectively http://www.streetinsider.com/PRNewswire/Medivir%27s+fostrox+%2B+Lenvima+confirm+promise+of+improved+outcomes+in+advanced+liver+cancer%2C+detailed+and+mature+data+presented+at+ESMO/23723647.html Mon, 16 Sep 2024 03:21:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Medivir%27s+fostrox+%2B+Lenvima+confirm+promise+of+improved+outcomes+in+advanced+liver+cancer%2C+detailed+and+mature+data+presented+at+ESMO/23723647.html <div class="xn-content"> <ul type="disc"><li><i>Mature results from Medivir's phase 1b / 2a open label trial of fostrox + Lenvima® confirm improved outcomes in second-line advanced liver cancer with a median time to progression (TTP) of 10.9 months¹ (4.1 – 18.1).</i></li><li><i>The results showed an objective response (ORR) of 24%, and a median duration of response of 7.0 months.</i></li><li><i>Detailed safety update reinforces the ability to combine fostrox and Lenvima long-term, only 1 patient discontinuing fostrox due to adverse events.</i></li><li><i>Medivir's fostrox (fostroxacitabine bralpamide) is the only orally-administered, liver-targeted inhibitor of DNA replication. Its unique mechanism for the treatment of liver cancer delivers the cell-killing compound selectively http://www.streetinsider.com/Press+Releases/Medivir%27s+fostrox+%2B+Lenvima+confirm+promise+of+improved+outcomes+in+advanced+liver+cancer%2C+detailed+and+mature+data+presented+at+ESMO/23723647.html Mon, 16 Sep 2024 03:21:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Medivir%27s+fostrox+%2B+Lenvima+confirm+promise+of+improved+outcomes+in+advanced+liver+cancer%2C+detailed+and+mature+data+presented+at+ESMO/23723647.html <div class="xn-content"> <ul type="disc"><li><i>Mature results from Medivir's phase 1b / 2a open label trial of fostrox + Lenvima® confirm improved outcomes in second-line advanced liver cancer with a median time to progression (TTP) of 10.9 months¹ (4.1 – 18.1).</i></li><li><i>The results showed an objective response (ORR) of 24%, and a median duration of response of 7.0 months.</i></li><li><i>Detailed safety update reinforces the ability to combine fostrox and Lenvima long-term, only 1 patient discontinuing fostrox due to adverse events.</i></li><li><i>Medivir's fostrox (fostroxacitabine bralpamide) is the only orally-administered, liver-targeted inhibitor of DNA replication. Its unique mechanism for the treatment of liver cancer delivers the cell-killing compound selectively http://www.streetinsider.com/PRNewswire/Medivir%27s+fostrox+%2B+Lenvima+confirm+promise+of+improved+outcomes+in+advanced+liver+cancer%2C+detailed+and+mature+data+presented+at+ESMO/23723647.html Mon, 16 Sep 2024 03:21:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Medivir+to+present+mature+clinical+data+for+fostrox+%2B+Lenvima+at+ESMO+Conference+and+to+host+a+webcast+on+September+16/23715090.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Sept. 12, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(NASDAQ Stockholm: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, has previously announced that detailed and mature data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the <span>European Society for Medical Oncology (ESMO) Congress</span> in <location value="LU/es..barcel" idsrc="xmltag.org" >Barcelona</location>, <chron>September 16, 2024</chron>.</p> <p>The abstract, titled<i> "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) http://www.streetinsider.com/Press+Releases/Medivir+to+present+mature+clinical+data+for+fostrox+%2B+Lenvima+at+ESMO+Conference+and+to+host+a+webcast+on+September+16/23715090.html Thu, 12 Sep 2024 07:26:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Medivir+to+present+mature+clinical+data+for+fostrox+%2B+Lenvima+at+ESMO+Conference+and+to+host+a+webcast+on+September+16/23715090.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Sept. 12, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(NASDAQ Stockholm: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, has previously announced that detailed and mature data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the <span>European Society for Medical Oncology (ESMO) Congress</span> in <location value="LU/es..barcel" idsrc="xmltag.org" >Barcelona</location>, <chron>September 16, 2024</chron>.</p> <p>The abstract, titled<i> "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) http://www.streetinsider.com/PRNewswire/Medivir+to+present+mature+clinical+data+for+fostrox+%2B+Lenvima+at+ESMO+Conference+and+to+host+a+webcast+on+September+16/23715090.html Thu, 12 Sep 2024 07:26:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Medivir+to+present+mature+clinical+data+for+fostrox+%2B+Lenvima+at+ESMO+Conference+and+to+host+a+webcast+on+September+16/23715090.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Sept. 12, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(NASDAQ Stockholm: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, has previously announced that detailed and mature data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the <span>European Society for Medical Oncology (ESMO) Congress</span> in <location value="LU/es..barcel" idsrc="xmltag.org" >Barcelona</location>, <chron>September 16, 2024</chron>.</p> <p>The abstract, titled<i> "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) http://www.streetinsider.com/Press+Releases/Medivir+to+present+mature+clinical+data+for+fostrox+%2B+Lenvima+at+ESMO+Conference+and+to+host+a+webcast+on+September+16/23715090.html Thu, 12 Sep 2024 07:26:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Medivir+to+present+mature+clinical+data+for+fostrox+%2B+Lenvima+at+ESMO+Conference+and+to+host+a+webcast+on+September+16/23715090.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Sept. 12, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(NASDAQ Stockholm: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, has previously announced that detailed and mature data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the <span>European Society for Medical Oncology (ESMO) Congress</span> in <location value="LU/es..barcel" idsrc="xmltag.org" >Barcelona</location>, <chron>September 16, 2024</chron>.</p> <p>The abstract, titled<i> "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) http://www.streetinsider.com/PRNewswire/Medivir+to+present+mature+clinical+data+for+fostrox+%2B+Lenvima+at+ESMO+Conference+and+to+host+a+webcast+on+September+16/23715090.html Thu, 12 Sep 2024 07:26:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Medivir+to+present+updated+clinical+data+for+fostrox+%2B+Lenvima+in+HCC+at+ESMO+Conference+in+September/23476335.html <div class="xn-content"> <p><span class="legendSpanClass">STOCKHOLM </span>, <span class="legendSpanClass"><chron>July 18, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(NASDAQ: MVIR) (STOCKHOLM: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, is pleased to announce that updated data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) has been accepted for presentation at the <span>European Society for Medical Oncology (ESMO) Congress</span> in <location value="LU/es..barcel" idsrc="xmltag.org" >Barcelona</location>, <chron>September 13-17, 2024</chron>.</p> <p>The abstract, titled<i> "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed http://www.streetinsider.com/Press+Releases/Medivir+to+present+updated+clinical+data+for+fostrox+%2B+Lenvima+in+HCC+at+ESMO+Conference+in+September/23476335.html Thu, 18 Jul 2024 03:08:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Medivir+to+present+updated+clinical+data+for+fostrox+%2B+Lenvima+in+HCC+at+ESMO+Conference+in+September/23476335.html <div class="xn-content"> <p><span class="legendSpanClass">STOCKHOLM </span>, <span class="legendSpanClass"><chron>July 18, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(NASDAQ: MVIR) (STOCKHOLM: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, is pleased to announce that updated data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) has been accepted for presentation at the <span>European Society for Medical Oncology (ESMO) Congress</span> in <location value="LU/es..barcel" idsrc="xmltag.org" >Barcelona</location>, <chron>September 13-17, 2024</chron>.</p> <p>The abstract, titled<i> "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed http://www.streetinsider.com/PRNewswire/Medivir+to+present+updated+clinical+data+for+fostrox+%2B+Lenvima+in+HCC+at+ESMO+Conference+in+September/23476335.html Thu, 18 Jul 2024 03:08:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Medivir+to+present+updated+clinical+data+for+fostrox+%2B+Lenvima+in+HCC+at+ESMO+Conference+in+September/23476335.html <div class="xn-content"> <p><span class="legendSpanClass">STOCKHOLM </span>, <span class="legendSpanClass"><chron>July 18, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(NASDAQ: MVIR) (STOCKHOLM: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, is pleased to announce that updated data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) has been accepted for presentation at the <span>European Society for Medical Oncology (ESMO) Congress</span> in <location value="LU/es..barcel" idsrc="xmltag.org" >Barcelona</location>, <chron>September 13-17, 2024</chron>.</p> <p>The abstract, titled<i> "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed http://www.streetinsider.com/Press+Releases/Medivir+to+present+updated+clinical+data+for+fostrox+%2B+Lenvima+in+HCC+at+ESMO+Conference+in+September/23476335.html Thu, 18 Jul 2024 03:08:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Medivir+to+present+updated+clinical+data+for+fostrox+%2B+Lenvima+in+HCC+at+ESMO+Conference+in+September/23476335.html <div class="xn-content"> <p><span class="legendSpanClass">STOCKHOLM </span>, <span class="legendSpanClass"><chron>July 18, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(NASDAQ: MVIR) (STOCKHOLM: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need</b>, is pleased to announce that updated data from the phase 1b/2a study of fostrox (fostroxacitabine) in combination with Lenvima® (lenvatinib) for the treatment of advanced hepatocellular carcinoma (HCC) has been accepted for presentation at the <span>European Society for Medical Oncology (ESMO) Congress</span> in <location value="LU/es..barcel" idsrc="xmltag.org" >Barcelona</location>, <chron>September 13-17, 2024</chron>.</p> <p>The abstract, titled<i> "Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed http://www.streetinsider.com/PRNewswire/Medivir+to+present+updated+clinical+data+for+fostrox+%2B+Lenvima+in+HCC+at+ESMO+Conference+in+September/23476335.html Thu, 18 Jul 2024 03:08:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Number+of+shares+and+votes+in+Medivir+AB+on+28+June+2024/23410601.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>June 28, 2024</chron></span> /PRNewswire/ --<b> Medivir AB </b>(NASDAQ: MVIR) (STOCKHOLM: MVIR) today announces that the number of shares and votes in Medivir has changed during <chron>June 2024</chron> as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on <chron>7 May 2024</chron>. Both the issue and the reclassification have been previously announced through a separate press release.</p> <p>Today, the last trading day of http://www.streetinsider.com/Press+Releases/Number+of+shares+and+votes+in+Medivir+AB+on+28+June+2024/23410601.html Fri, 28 Jun 2024 05:00:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Number+of+shares+and+votes+in+Medivir+AB+on+28+June+2024/23410601.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>June 28, 2024</chron></span> /PRNewswire/ --<b> Medivir AB </b>(NASDAQ: MVIR) (STOCKHOLM: MVIR) today announces that the number of shares and votes in Medivir has changed during <chron>June 2024</chron> as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on <chron>7 May 2024</chron>. Both the issue and the reclassification have been previously announced through a separate press release.</p> <p>Today, the last trading day of http://www.streetinsider.com/PRNewswire/Number+of+shares+and+votes+in+Medivir+AB+on+28+June+2024/23410601.html Fri, 28 Jun 2024 05:00:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Number+of+shares+and+votes+in+Medivir+AB+on+28+June+2024/23410601.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>June 28, 2024</chron></span> /PRNewswire/ --<b> Medivir AB </b>(NASDAQ: MVIR) (STOCKHOLM: MVIR) today announces that the number of shares and votes in Medivir has changed during <chron>June 2024</chron> as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on <chron>7 May 2024</chron>. Both the issue and the reclassification have been previously announced through a separate press release.</p> <p>Today, the last trading day of http://www.streetinsider.com/Press+Releases/Number+of+shares+and+votes+in+Medivir+AB+on+28+June+2024/23410601.html Fri, 28 Jun 2024 05:00:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Number+of+shares+and+votes+in+Medivir+AB+on+28+June+2024/23410601.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>June 28, 2024</chron></span> /PRNewswire/ --<b> Medivir AB </b>(NASDAQ: MVIR) (STOCKHOLM: MVIR) today announces that the number of shares and votes in Medivir has changed during <chron>June 2024</chron> as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on <chron>7 May 2024</chron>. Both the issue and the reclassification have been previously announced through a separate press release.</p> <p>Today, the last trading day of http://www.streetinsider.com/PRNewswire/Number+of+shares+and+votes+in+Medivir+AB+on+28+June+2024/23410601.html Fri, 28 Jun 2024 05:00:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Fostrox+%2B+Lenvima%C2%AE+holds+promise+of+greatly+improved+outcomes+for+advanced+liver+cancer+patients%2C+reveals+new+data+from+Medivir+at+ESMO+GI/23403571.html <div class="xn-content"> <ul type="disc"><li><i>New results from Medivir's Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population </i></li><li><i>Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to progression (TTP) of 10.8 months</i><i>¹</i><i> (4.1 – NE) – with one patient still on treatment after 22 months</i></li><li><i>Results come despite very poor prognosis for most second-line HCC patients today, with just 5 – 10% responding to current standard of care treatment, and a typical TTP of only 3 - 4 months</i></li><li><i>Medivir's fostrox (fostroxacitabine http://www.streetinsider.com/Press+Releases/Fostrox+%2B+Lenvima%C2%AE+holds+promise+of+greatly+improved+outcomes+for+advanced+liver+cancer+patients%2C+reveals+new+data+from+Medivir+at+ESMO+GI/23403571.html Thu, 27 Jun 2024 03:22:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Fostrox+%2B+Lenvima%C2%AE+holds+promise+of+greatly+improved+outcomes+for+advanced+liver+cancer+patients%2C+reveals+new+data+from+Medivir+at+ESMO+GI/23403571.html <div class="xn-content"> <ul type="disc"><li><i>New results from Medivir's Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population </i></li><li><i>Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to progression (TTP) of 10.8 months</i><i>¹</i><i> (4.1 – NE) – with one patient still on treatment after 22 months</i></li><li><i>Results come despite very poor prognosis for most second-line HCC patients today, with just 5 – 10% responding to current standard of care treatment, and a typical TTP of only 3 - 4 months</i></li><li><i>Medivir's fostrox (fostroxacitabine http://www.streetinsider.com/PRNewswire/Fostrox+%2B+Lenvima%C2%AE+holds+promise+of+greatly+improved+outcomes+for+advanced+liver+cancer+patients%2C+reveals+new+data+from+Medivir+at+ESMO+GI/23403571.html Thu, 27 Jun 2024 03:22:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Fostrox+%2B+Lenvima%C2%AE+holds+promise+of+greatly+improved+outcomes+for+advanced+liver+cancer+patients%2C+reveals+new+data+from+Medivir+at+ESMO+GI/23403571.html <div class="xn-content"> <ul type="disc"><li><i>New results from Medivir's Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population </i></li><li><i>Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to progression (TTP) of 10.8 months</i><i>¹</i><i> (4.1 – NE) – with one patient still on treatment after 22 months</i></li><li><i>Results come despite very poor prognosis for most second-line HCC patients today, with just 5 – 10% responding to current standard of care treatment, and a typical TTP of only 3 - 4 months</i></li><li><i>Medivir's fostrox (fostroxacitabine http://www.streetinsider.com/Press+Releases/Fostrox+%2B+Lenvima%C2%AE+holds+promise+of+greatly+improved+outcomes+for+advanced+liver+cancer+patients%2C+reveals+new+data+from+Medivir+at+ESMO+GI/23403571.html Thu, 27 Jun 2024 03:22:00 -0500 MVIR MVIR http://www.streetinsider.com/PRNewswire/Fostrox+%2B+Lenvima%C2%AE+holds+promise+of+greatly+improved+outcomes+for+advanced+liver+cancer+patients%2C+reveals+new+data+from+Medivir+at+ESMO+GI/23403571.html <div class="xn-content"> <ul type="disc"><li><i>New results from Medivir's Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population </i></li><li><i>Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to progression (TTP) of 10.8 months</i><i>¹</i><i> (4.1 – NE) – with one patient still on treatment after 22 months</i></li><li><i>Results come despite very poor prognosis for most second-line HCC patients today, with just 5 – 10% responding to current standard of care treatment, and a typical TTP of only 3 - 4 months</i></li><li><i>Medivir's fostrox (fostroxacitabine http://www.streetinsider.com/PRNewswire/Fostrox+%2B+Lenvima%C2%AE+holds+promise+of+greatly+improved+outcomes+for+advanced+liver+cancer+patients%2C+reveals+new+data+from+Medivir+at+ESMO+GI/23403571.html Thu, 27 Jun 2024 03:22:00 -0500 MVIR MVIR http://www.streetinsider.com/Press+Releases/Medivir+selects+global+CRO+partner+for+upcoming+phase+2b+study+in+HCC+with+fostrox+%2B+Lenvima+and+initiates+study+feasibility/23374414.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>June 19, 2024</chron></span> /PRNewswire/ -- <b>Medivir AB </b>(NASDAQ: MVIR) (STOCKHOLM: MVIR)<b>, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, </b>announced today that it has selected a global CRO partner for the planned phase 2b study evaluating fostroxacitabine bralpamide (fostrox) + Lenvima® vs Lenvima alone in second line HCC.</p> <p>In the next phase of development, Medivir is planning for a global, randomized phase 2b study aligned with its recent supportive Type C interaction with the FDA. The objective is to evaluate the combination of fostrox + http://www.streetinsider.com/Press+Releases/Medivir+selects+global+CRO+partner+for+upcoming+phase+2b+study+in+HCC+with+fostrox+%2B+Lenvima+and+initiates+study+feasibility/23374414.html Wed, 19 Jun 2024 04:35:00 -0500 MVIR MVIR